Results 101 to 110 of about 1,874,188 (207)

The projected impact of geographic targeting of oral cholera vaccination in sub-Saharan Africa: A modeling study.

PLoS Medicine, 2019
BACKGROUND:Cholera causes an estimated 100,000 deaths annually worldwide, with the majority of burden reported in sub-Saharan Africa. In May 2018, the World Health Assembly committed to reducing worldwide cholera deaths by 90% by 2030.
Elizabeth C Lee, Andrew S Azman, Joshua Kaminsky, Sean M Moore, Heather S McKay, Justin Lessler   +5 more
doaj   +1 more source

Protection afforded by oral cholera vaccine CVD 103-HgR against diarrhea following subsequent experimental challenge [10].

, 2018
Protection afforded by oral cholera vaccine CVD 103-HgR against diarrhea following subsequent experimental challenge [10].
Jakub K. Simon (397457), Edward T. Ryan (88542), Kamrul Islam (430894), Peng Xu (17962), Marc Gurwith (325946), Michael Lock (3050382), Firdausi Qadri (89170), Motaher Hossain (3337707), Pavol Kováč (585324), Mitchell Cohen (713855), Beth D. Kirkpatrick (150711), Jason B. Harris (89164), Regina C. LaRocque (89165), Richelle C. Charles (192294), Douglas Haney (5071247), Meagan Kelly (4961773), Caroline E. Lyon (5071244), Myron M. Levine (130627), Taufiqur Rahman Bhuiyan (336624), Wilbur H. Chen (3682060), Stephen B. Calderwood (88541), Leslie M. Mayo Smith (5071250)   +21 more
core   +1 more source

Investigations into the safety and immunogenicity of a killed oral cholera vaccine developed in Viet Nam

Bulletin of the World Health Organization, 2002
OBJECTIVE: To evaluate a killed oral cholera vaccine produced in Viet Nam, and to compare the Vietnamese vaccine with one that is licensed internationally.
Trach D.D., Cam P.D., Ke N.T., Rao M.R., Dinh D., Hang P.V., Hung N.V., Canh D.G., Thiem V.D., Naficy A., Ivanoff B., Svennerholm A-M., Holmgren J., Clemens J.D.   +13 more
doaj  

Estimated response times to mount a mass oral cholera vaccination campaign, using a two-dose vaccine.

, 2013
Estimated response times to mount a mass oral cholera vaccination campaign, using a two-dose vaccine.
Mohamed S. Jiddawi (148765), Jacqueline L. Deen (148731), Anna L. Lopez (356996), Rebecca F. Grais (38515), Dipika Sur (82436), Sujit K. Bhattacharya (92308), John D. Clemens (148728), Lorenz von Seidlein (45473), Rita Reyburn (130140)   +8 more
core   +1 more source

Vaccine specific immune response to an inactivated oral cholera vaccine and EPI vaccines in a high and low arsenic area in Bangladeshi children

, 2013
Immune responses to the inactivated oral whole cell cholera toxin B (CTB) subunit cholera vaccine, Dukoral(®), as well as three childhood vaccines in the national immunization system were compared in children living in high and low arsenic contaminated ...
Sultana, Gazi Nurun Nahar, Nazim, Mohammad, Chowdhury, Mohiul, Alam, Mohammad Murshid, Svennerholm, Ann-Mari,, Saha, Amit, Hossain, Mohammad Bakhtiar, Hore, Samar Kumar, Qadri, Firdausi, Ahmed, Tanvir,   +9 more
core   +1 more source

Cases that would have been prevented by mass oral vaccination oral cholera vaccine in three endemic sites.

, 2013
Mass vaccination is presumed to be using the currently licensed two-dose oral cholera vaccine at varying response times and vaccine coverage.
Mohamed S. Jiddawi (148765), Jacqueline L. Deen (148731), Anna L. Lopez (356996), Rebecca F. Grais (38515), Dipika Sur (82436), Sujit K. Bhattacharya (92308), John D. Clemens (148728), Lorenz von Seidlein (45473), Rita Reyburn (130140)   +8 more
core   +1 more source

Oral cholera vaccine given marketing authorisation in European Union

, 2004
At the end of April 2004, the European Medicines Agency (EMEA, http://www.emea.eu.int) issued a marketing authorisation (comparable to a product licence) applicable to all European Union countries for the oral cholera vaccine Dukoral, produced by Chiron ...
Collective Editorial team
core   +1 more source

Private demand for cholera vaccines in Beira, Mozambique.

, 2007
In the summer of 2005, we interviewed 996 randomly selected respondents in Beira, Mozambique concerning their willingness and ability to pay for cholera vaccine for themselves and for other household members.
Whittington, Dale, Cumbane, Arnaldo, Lazaro, Nivalda, Songane, Francisco F, Deen, Jacqueline, von Seidlein, Lorenz, Jeuland, Marc, Nyamete, Andrew, Lucas, Marcelino ES, MacMahon, Melissa, Barreto, Avertino   +10 more
core   +1 more source

Memory B Cell and Other Immune Responses in Children Receiving Two Doses of an Oral Killed Cholera Vaccine Compared to Responses following Natural Cholera Infection in Bangladesh

, 2019
Current oral cholera vaccines induce lower protective efficacy and shorter duration of protection against cholera than wild-type infection provides, and this difference is most pronounced in young children.
Leung, Daniel, Riyadh, M. Asrafuzzaman, Calderwood, Stephen, Alam, Mohammad Murshid, LaRocque, Regina, Khan, Ashraful Islam, Rahman, Mohammad Arif, Qadri, Firdausi, Mohasin, M., Ryan, Edward, Uddin, Taher, Patel, Sweta, Charles, Richelle, Harris, Jason, Saha, Amit, Khanam, Farhana, Chowdhury, Fahima, Aktar, Amena   +17 more
core   +1 more source

Biomodel for evaluating attenuated Vibrio cholerae strains as human cholera vaccine candidates. Study of toxigenicity, immunogenicity and protection

VacciMonitor, 2014
In many countries, Cholera remains being a problem for human health, since it continues being an epidemic or endemic disease, which affects either children or adults and it is a death cause when cholera cases are not treated.
Reynaldo Oliva-Hernández, Hilda María García-Sánchez, Juan Francisco Infante-Bourzac, José Luis Pérez- Quiñoy, Bárbara Cedré-Marrero, Tania Valmaseda-Pérez, Arturo Talavera-Coronel, Gemma Año-López, Viviana Margarita Pérez-Amat, Luís García-Imía   +9 more
doaj